On June 30, 2023, ALPINE IMMUNE SCIENCES ($NASDAQ:ALPN) announced their financial report for the second quarter of the fiscal year 2023. The total revenue for the quarter was USD 8.6 million, which is a 62.4% growth compared to the same period in the previous year. Additionally, the company reported a net income of -13.2 million for Q2, which is lower than the -18.1 million reported in the same quarter of the prior year.
On Monday, ALPINE IMMUNE SCIENCES reported impressive Q2 earnings for 2023. Its stock opened at $13.6 and closed at $13.2, down 2.4% from the previous closing price of $13.6. This increase was attributed to strong sales of its products and services. The impressive results were further bolstered by the strong performance of ALPINE IMMUNE SCIENCES’ research and development efforts. The company’s R&D investments resulted in a number of breakthroughs in products and services, which are expected to result in additional growth for the company in the future.
Additionally, the company saw an increase in its customer base, with more than triple the number of customers compared to the previous year. With its impressive revenue growth, operating income, and R&D investments, ALPINE IMMUNE SCIENCES is well-positioned to capitalize on potential future opportunities. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for ALPN. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for ALPN. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for ALPN. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for ALPN are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we performed an analysis of ALPINE IMMUNE SCIENCES’s wellbeing. According to our Star Chart, ALPINE IMMUNE SCIENCES is classified as a ‘rhino’; a type of company that has achieved moderate revenue or earnings growth. When looking at potential investors, ALPINE IMMUNE SCIENCES appeals to those who are interested in long-term, moderate growth. In terms of health, ALPINE IMMUNE SCIENCES has an intermediate score of 4/10 with regards to its cashflows and debt. This indicates that the company is likely to safely ride out any crisis without the risk of going bankrupt. Looking at specific areas of performance, ALPINE IMMUNE SCIENCES is strong in asset and growth but weak in dividend and profitability. More…
Risk Rating Analysis
Star Chart Analysis
Alpine Immune Sciences Inc is a biotechnology company that focuses on the treatment of cancer and autoimmune diseases. The company’s main competitors are Geovax Labs Inc, NeuBase Therapeutics Inc, and Immunome Inc. All three companies are similar in that they are all focused on the treatment of cancer and autoimmune diseases. However, each company has its own unique approach to treatment.
Geovax Labs Inc is a clinical stage biotechnology company, which focuses on the development of human vaccines. The company’s vaccine candidates are based on its proprietary Modified Vaccinia Ankara platform. Its pipeline includes HIV/AIDS, Zika, and hemorrhagic fever vaccines. Geovax Labs Inc was founded by Donald Francis and Harriet Robinson on April 4, 2001 and is headquartered in Atlanta, GA.
– NeuBase Therapeutics Inc ($NASDAQ:NBSE)
NeuBase Therapeutics Inc is a company that focuses on the development of treatments for patients with genetic diseases. The company has a market cap of 9.94 million as of 2022 and a return on equity of -60.73%. NeuBase Therapeutics Inc’s main focus is on the development of treatments for patients with genetic diseases. The company’s treatments aim to improve the quality of life for patients with genetic diseases. NeuBase Therapeutics Inc’s treatments are based on the latest scientific discoveries and aim to provide patients with the best possible care.
The company’s market cap is 55.66M as of 2022 and its ROE is -104.6%. The company is engaged in the research and development of monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company’s products are in clinical trials and have not yet been approved by the FDA.
Alpine Immune Sciences reported strong revenue growth for the second quarter of 2023, with total revenue increasing by 62.4% year-over-year. However, net income for the quarter declined to -13.2 million from -18.1 million in the year prior. For investors considering investing in Alpine Immune Sciences, these results indicate that the company is making progress towards achieving profitability while also achieving strong revenue growth. It is important to note, however, that with the company’s net income still in negative territory, risk-averse investors may want to wait for the company to become profitable before investing.